CHAIN Biotechnology was founded in 2014, by biotech entrepreneur Dr Edward Green, to exploit the therapeutic potential of beneficial Clostridia bacteria. CHAIN is based at MediCity in Nottingham with a head office in Marlow.

 

We use our knowledge of the gut microbiome and expertise in engineering biology and fermentation to develop superior live biotherapeutics. These are novel drugs based on living bacteria found in the gut but engineered to deliver specific therapeutic molecules. CHAIN works closely with the Synthetic Biology Research Centre in Nottingham, which has developed specialised molecular tools for engineering Clostridia.

 

CHAIN has built a proprietary live biotherapeutic platform (CADDTM), based on a single bacterial species, that supports multiple therapeutic products. CHAIN’s products address an unmet clinical need for safer, more effective and lower cost drugs. Our treatments for diseases associated with the human gut microbiome have the potential to transform healthcare across many chronic and debilitating diseases.

 

For example, CHAIN’s lead asset produces a potent anti-inflammatory for treating ulcerative colitis. CHAIN has demonstrated safety and efficacy in vivo, scaled and de-risked manufacture, and is now rapidly progressing this product towards the clinic. CHAIN is also developing several other products in parallel with a focus on infection, inflammation and metabolic disorders such as type 2 diabetes.

Board

Robert Rickman

Chairman

Dr Edward Green

Founder & Chief Executive

Dr Basil Omar

Founder & Chief Commercial Officer

Peter McPartland

Non-Executive Director

Philip Chu

Non-Executive Director

Management Team

Dr Edward Green

Founder & Chief Executive

Ben Bradley

Head of Partnerships and Licensing

Dr Daniela Heeg

Technical Product Manager

Advisory Team

Dr Stephen Taylor

Manufacturing

Michael Darsley

Regulatory

Dr Tim Davies

Manufacturing

Dr Mark Edwards

Scientific Advisor

Dr Edward Green

Founder & Chief Executive

Edward is a serial biotech entrepreneur, having founded Green Biologics and built it into a world leader for butanol fermentation. He is a microbiologist with over 25 years’ experience with anaerobic bacteria, obtaining a PhD in Biochemical Engineering from the University of Manchester Institute of Science and Technology. He has pioneered technical improvements in microbial strain improvement and fermentation process development for industrial biotechnology applications contributing to numerous scientific publications and patents. He recently founded CHAIN Biotech, a microbiome Company focused on development and commercialisation of microbial technology for the production and delivery of biotherapeutics. Edward participates in the IB Leadership Forum, several NIBB management boards; C1NET and LBNET and BBSRC advisory panels for Bioenergy and Industrial Biotechnology.

Dr Edward Green

Founder & Chief Executive

Edward is a serial biotech entrepreneur, having founded Green Biologics and built it into a world leader for butanol fermentation. He is a microbiologist with over 25 years’ experience with anaerobic bacteria, obtaining a PhD in Biochemical Engineering from the University of Manchester Institute of Science and Technology. He has pioneered technical improvements in microbial strain improvement and fermentation process development for industrial biotechnology applications contributing to numerous scientific publications and patents. He recently founded CHAIN Biotech, a microbiome Company focused on development and commercialisation of microbial technology for the production and delivery of biotherapeutics. Edward participates in the IB Leadership Forum, several NIBB management boards; C1NET and LBNET and BBSRC advisory panels for Bioenergy and Industrial Biotechnology.

Dr Basil Omar

Founder & Chief Commercial Officer

Basil has a PhD in Physics from Loughborough University and MBA from Warwick Business School. He has held senior technical management roles in semiconductors, electronic displays and advanced materials with Philips Electronics and Sharp Corporation. Basil also has a background in Management Consultancy with PRTM (now PwC) and Grant Thornton, and has held senior business development and marketing roles at Transco/National Grid and Green Biologics. Basil via Woodbridge Innovation has supported numerous early stage companies in a range of high tech fields including clean energy and industrial biotech. Basil launched and ran the University of Gloucestershire’s business incubation hubs and is co-founder of the Gloucestershire Angel Investment Network. Basil is a farming and classic car enthusiast.

Dr Basil Omar

Founder & Chief Commercial Officer

Basil has a PhD in Physics from Loughborough University and MBA from Warwick Business School. He has held senior technical management roles in semiconductors, electronic displays and advanced materials with Philips Electronics and Sharp Corporation. Basil also has a background in Management Consultancy with PRTM (now PwC) and Grant Thornton, and has held senior business development and marketing roles at Transco/National Grid and Green Biologics. Basil via Woodbridge Innovation has supported numerous early stage companies in a range of high tech fields including clean energy and industrial biotech. Basil launched and ran the University of Gloucestershire’s business incubation hubs and is co-founder of the Gloucestershire Angel Investment Network. Basil is a farming and classic car enthusiast.

Ben Bradley

Head of Partnerships and Licensing

Ben has a first class BSc in Molecular Genetics in Biotechnology from Sussex University and an MSc in Applied Biosciences and Biotechnology from Imperial College (awarded top student). Ben also spent a year at GSK working in Bioinformatics. Prior to joining CHAIN Ben gained sales and business development skills working as a recruiter for top tier investment banks. Outside of science and business, Ben has been a successful personal trainer and swimming coach and continues to compete at masters’ swimming events.

Dr Daniela Heeg

Technical Product Manager

Daniela earned her PhD as part of the Marie Curie Network CLOSTNET at the University of Nottingham working on Clostridium difficile spores. She continued her work on Clostridium difficile as a postdoc in Nigel Minton’s Clostridia Research Group, before joining the diagnostic company Micropathology Ltd in 2014. Daniela joins CHAIN as Technical Product Manager to oversee development and global distribution of CHAIN’s modular plasmids.​ Her extensive background and expertise in Clostridium research and technology makes her a valuable addition to the CHAIN team. Outside of Clostridia, Daniela is an avid touch rugby and cycling enthusiast.

Robert Rickman

Chairman

Robert is a director of LSE listed Schroder UK Midcap Investment Trust and a director of Rockley Photonics Ltd a silicon photonics components company with operations in the UK, USA, Finland and China as well as a number of other private companies. He has also been a director of Carclo plc a London listed plastics company, a director of telecoms components business Bookham Technology plc (listed on LSE & Nasdaq in 2000) and Oxitec, an insect genetics company, sold to Intrexon in 2015 for £100m.

Dr Stephen Taylor

Board Advisor

Steve has a PhD in Biochemistry from Warwick and has worked for ICI, AstraZeneca, Avecia, MSD and most recently Fujifilm Diosynth as Senior Vice President responsible for Commercial. His expertise is in biopharma development, manufacture and commercialisation. After 10 years in biotech R&D, Steve was a founder of Avecia Biologics and led business development to build a global biologics CDMO with operations in USA and UK and a customer base covering pharma and biotech across North America, Asia and Europe. The business is now part of the Fujifilm Group. Steve served on the BIA board 2013-2016 and has been a major voice in promoting the UK as a centre for biopharma development currently on the Medicines Manufacturing Industry Partnership steering team. Steve is now an independent consultant.

Peter McPartland

Non-Executive Director

Peter is an independent, venture capital consultant, with over 25 years’ experience in the life sciences sector. He trained initially at Schroder Ventures (now Permira) before becoming a co-founder, general partner, then venture partner at SV Life Sciences (now SV Health Investors). Since 2007 he has operated on a freelance basis. Over his career, he has been involved with over 30 start-ups and early stage life science businesses, including Shire Pharmaceuticals, Chiroscience and Triangle Pharmaceuticals.

Philip Chu

Non-Executive Director

Philip is a private investor based in Hong Kong specialising in life science companies.

Michael Darsley

Regulatory

Michael is an experienced director of in-house and outsourced Biologics and Vaccines R&D. Built and led teams outsourcing process development and clinical trial supply manufacturing for recombinant protein and live attenuated vaccines. Gained regulatory approval to move several engineered microbes into the clinic.

Dr Tim Davies

Manufacturing Advisor

Tim is an experienced R&D biotech manager (ex CTO at Green Biologics Ltd). he has a track record in microbial fermentation process optimisation, scale-up, and protein purification.

Dr Mark Edwards

Scientific Advisor

Mark is a life scientist with over 30 years of experience in the biotech industry and an applied research background in biochemistry, microbiology and genetic engineering. He has held managment roles with GD Searle, British Biotech and Oxagen (Founder).